Nachrichten zur Royalty Pharma plc Aktie

Royalty Pharma Appoints Kenneth Sun as Senior Vice President and Head of Asia to Expand Royalty Pharmas Global Platform

NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of…

Royalty Pharma and Zymeworks Enter Into $250 Million Royalty-Backed Note Financing

NEW YORK and VANCOUVER, British Columbia, March 02, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and…

Zymeworks and Royalty Pharma Enter into $250 Million Royalty-Backed Note Financing

VANCOUVER, British Columbia and NEW YORK, March 02, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) and Royalty Pharma…

Cytokinetics (CYTK) Q4 2025 Earnings Transcript

Image source: The Motley Fool.DateTuesday, February 24, 2026 at 4:30 p.m. ETCall participantsPresident and Chief Executive Officer — Robert I.…

Royalty Pharma: 2025 Financial Performance And Strategic Outlook

…

Royalty Pharma Reports Q4 and Full Year 2025 Results

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

Royalty Pharma (RPRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

TEVA Signs Deal With RPRX to Accelerate Development of Vitiligo Drug

Teva strikes a $500M funding deal with Royalty Pharma for the speedy development of its vitiligo candidate, TEV-408, while keeping…

Royalty Pharma and Teva Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

NEW YORK and PARSIPPANY, N.J., Jan. 11, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Teva…

Teva and Royalty Pharma Enter Agreement to Accelerate Development of Potential Treatment for Vitiligo

PARSIPPANY, N.J., and NEW YORK, Jan. 11, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva…

Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board…

Royalty Pharma Acquires Remaining Royalty Interest in Roche’s Evrysdi for $240 Million and Potential Milestones

Royalty Pharma will now own 100% of the 8% to 16% Evrysdi royalty following multiple transactions with PTC since 2020…

Denali Enters Into a $275M Funding Deal With Royalty Pharma

DNLI secures a $275M funding deal with Royalty Pharma tied to potential approvals for its Hunter syndrome therapy.…

Royalty Pharma Acquires Royalty Interest in Alnylam’s AMVUTTRA for $310 Million from Blackstone Life Sciences

NEW YORK and CAMBRIDGE, Mass., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced…

Royalty Pharma Declares Fourth Quarter 2025 Dividend

NEW YORK, Oct. 17, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma plc (RPRX) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript

…

Royalty Pharma stock hits 52-week high at 37.91 USD By Investing.com

Royalty Pharma stock hits 52-week high at 37.91 USD…

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

Royalty Pharma (RPRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Royalty Pharma stock hits 52-week high at 36.89 USD By Investing.com

Royalty Pharma stock hits 52-week high at 36.89 USD…

Royalty Pharma at Goldman Sachs Conference: Strategic Growth Insights By Investing.com

Royalty Pharma at Goldman Sachs Conference: Strategic Growth Insights…

Royalty Pharma Completes the Acquisition of Its External Manager

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has…

Royalty Pharma Announces Shareholder Approval of its External Manager Acquisition

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly…

Royalty Pharma (RPRX) Reports Q1 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Royalty Pharma (RPRX) give a sense of how the business performed in the…

Unlocking Q1 Potential of Royalty Pharma (RPRX): Exploring Wall Street Estimates for Key Metrics

Looking beyond Wall Streets top -and-bottom-line estimate forecasts for Royalty Pharma (RPRX), delve into some of its key metrics to…

Royalty Pharma (RPRX) Earnings Expected to Grow: What to Know Ahead of Next Weeks Release

Royalty Pharma (RPRX) doesnt possess the right combination of the two key ingredients for a likely earnings beat in its…

Royalty Pharma Declares Second Quarter 2025 Dividend

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Royalty Pharma to Present at TD Cowen’s 45th Annual Health Care Conference

NEW YORK, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Heres What Key Metrics Tell Us About Royalty Pharma (RPRX) Q4 Earnings

The headline numbers for Royalty Pharma (RPRX) give insight into how the company performed in the quarter ended December 2024,…

Royalty Pharma reports Q4 results

…

Royalty Pharma Reports Q4 and Full Year 2024 Results

NEW YORK, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma stock rises following RP Management buyout and $3 billion buyback plan By Investing.com

Royalty Pharma stock rises following RP Management buyout and $3 billion buyback plan…

Royalty Pharma Announces Transformative Step in Company’s Evolution With Acquisition of its External Manager and $3 Billion Share Repurchase Program

NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced two major steps…

Royalty Pharma Announces Dividend Increase

NEW YORK, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board…

3 High-Yield Dividend Stocks to Buy in 2025 and Hold for a Decade or Longer

The benchmark S&P 500 index keeps reaching new highs, but not all of its components have participated in the rally.…

2 Exceptional Dividend Stocks Near 52-Week Lows You Could Regret Not Buying on the Dips

The benchmark stock indexes keep climbing to new heights, but there are plenty of attractive wallflowers at this dance. A…

3 High-Yield Dividend Growth Stocks to Buy in December and Hold for a Decade or Longer

Its been a great couple of years for the stock market. From the end of 2022 through Nov. 29, the…

Royalty Pharma to Present at Upcoming Investor Conferences

NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy +

…

3 High-Yield Dividend Stocks You Can Buy With $130 Now and Hold at Least a Decade

This has been an amazing year for stocks. From the end of 2023 through Nov. 12, the benchmark S&P 500…

Royalty Pharma: Massive Opportunity Ahead

…

Royalty Pharma Reports Third Quarter 2024 Results

NEW YORK, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for…

Royalty Pharma to Announce Third Quarter 2024 Financial Results on November 6, 2024

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will…

Royalty Pharma Declares Fourth Quarter 2024 Dividend

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…

Brain Biotech und der 128-Millionen-Euro-Deal - der "Big Deal" hat sein "Kleingedrucktes"

Brain Biotech verkauft ihre Lizenzrechte an dem Wirkstoff-Projekt Deucrictibant an Royalty Pharma. Den Erlös beziffert die Gesellschaft auf bis zu…

EQS-Adhoc: BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für den investigativen Pharmawirkstoff Deucrictibant mit Royalty Pharma ab (deutsch)

BRAIN Biotech AG schließt eine Vereinbarung über die Monetarisierung von Lizenzgebühren in Höhe von bis zu 128,88 Mio. EUR für…

Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the Yorvipath U.S. commercial launch, and general…

Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement

Proceeds to support continued development and commercialization of Endocrine Rare Disease products, including the YORVIPATH® U.S. commercial launch, and general…

Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating

…

Royalty Pharma plc (RPRX) Q2 2024 Earnings Call Transcript

…

Royalty Pharma Declares Third Quarter 2024 Dividend

NEW YORK, July 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX)…